Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- Early onset dementia more common than previously reported - 26th July 2024
- Children’s Exposome Linked to Serum Metabolite Changes - 24th July 2024
- Is Melatonin the wonder drug of anti-aging? - 22nd July 2024